0000899243-20-025332.txt : 20200916 0000899243-20-025332.hdr.sgml : 20200916 20200916163704 ACCESSION NUMBER: 0000899243-20-025332 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200914 FILED AS OF DATE: 20200916 DATE AS OF CHANGE: 20200916 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Olson Lisa CENTRAL INDEX KEY: 0001824009 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38541 FILM NUMBER: 201179195 MAIL ADDRESS: STREET 1: C/O MAGENTA THERAPEUTICS, INC. STREET 2: 100 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Magenta Therapeutics, Inc. CENTRAL INDEX KEY: 0001690585 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 TECHNOLOGY SQUARE STREET 2: 5TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-201-2700 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY SQUARE STREET 2: 5TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-14 0 0001690585 Magenta Therapeutics, Inc. MGTA 0001824009 Olson Lisa C/O MAGENTA THERAPEUTICS, INC. 100 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 0 1 0 0 See Remarks Stock Option (Right to Buy) 7.77 2020-09-14 4 A 0 120000 0.00 A 2030-09-13 Common Stock 120000 120000 D 25% of this option shall vest and become exercisable on September 14, 2021, with the remainder vesting in 36 equal monthly installments thereafter. Head of Research and Chief Scientific Officer /s/ Zoran Zdraveski, Attorney-in-Fact for Lisa Olson 2020-09-16